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Introduction
============

Sudden cardiac death (SCD) is defined as a sudden and unexpected cessation of cardiac activity leading to compromised blood flow to the brain and other vital organs. The event is called aborted SCD (also referred to as sudden cardiac arrest) if the abnormal rhythm is reverted back to normal rhythm (spontaneously or by intervention such as defibrillation) \[[@REF1]\]. In patients with structural heart disease, ventricular fibrillation is the most common cause of sudden cardiac arrest \[[@REF1]-[@REF2]\]. External defibrillation was found effective in terminating ventricular fibrillation and hence, implantable cardiac defibrillator (ICD) was developed and approved by the Food and Drug Authority in 1985 for secondary prevention only (which means for patients that had survived a cardiac arrest) in the vulnerable population. These devices further cemented the demonstrated reduction in mortality by converting shockable rhythms automatically in ischemic cardiomyopathy patient \[[@REF3]-[@REF4]\] and in non-ischemic cardiomyopathy patients \[[@REF5]\]. However, a significant number of patients have an increased risk but do not qualify for implantation of ICD because of multiple reasons such as, but not limited to, unestablished chronicity of cardiomyopathy or active infection. ICDs are expensive devices that are invasive and difficult to reverse. Many arrhythmias occur early during the course of cardiomyopathy. Patients remain unprotected during this early phase as guidelines mandate a waiting period to ensure that the deterioration in cardiac function is irreversible. Wearable cardioverter defibrillator (WCD) is a device which can detect and treat the ventricular tachycardia (VT) and ventricular fibrillation. WCD has been presented as the solution to bridge this vulnerable population to the implantable device during the waiting period. WCD is a vest which is worn and requires custom fitting to avoid electrical noise. It detects and defibrillates/cardioverts the abnormal rhythms through electrical electrodes.

The purpose of this study was to analyze our experience at Fairview Hospital, a community hospital in the Cleveland Clinic Health System, in terms of appropriateness of prescription of this wearable device and outcomes reflecting the safety and efficacy of this device. New technologies often have to overcome many hurdles in the phase of early adoption. One of these is an inappropriate prescription as the prescriber's grapple with the appropriate indications for the device. Another common issue is the safety of new devices that are also the focus of post-marketing analyses. We sought to review our records for a two-year period to make an assessment regarding these variables with WCD usage at our center.

Materials and methods
=====================

Study design

This was a retrospective observational study which was conducted from January 2014 to June 2016. The study was conducted on patients admitted to Fairview Hospital in Cleveland. The study was approved by the Institutional Review Board of the Cleveland Clinic and the individual consent was waived as it was a retrospective study.

Seventy-three patients that were prescribed and fitted with the WCD (LifeVest®, ZOLL, Pittsburgh, Pennsylvania) during this period were identified. The inclusion criteria comprised of patients with age more than 18 and with a documented diagnosis indicating the prescription of a WCD based on documented ejection fraction (EF). The exclusion criteria included people who had an ICD, congenital heart disease, and patients who were lost to follow-up. Patient\'s records were reviewed for any delivered shocks and then validated with Zoll© (manufacturer of LifeVest®). After excluding 23 patients due to lack of adequate follow up, the final sample size of 50 (n=50) was analyzed for safety and efficacy outcomes.

Data collection

We collected data in Microsoft Excel and data safety was ensured by the usage of IronKey© for data sharing. Data was collected for age, gender, race, diagnosis, diabetes, hypertension, chronic kidney disease, history of coronary artery disease, history of congestive heart failure, use of antiarrhythmic drugs, last cardiac catheterization, findings on cardiac catheterization, EF, source of EF, and fit date for the WCD. Follow-up was assessed with the follow-up date, follow-up EF, and difference in the EF. The primary outcome was eventual ICD placement and the secondary outcome was delivery of shock, including both appropriate and inappropriate.

Statistical analysis

Data was analyzed using Statistical Package for the Social Sciences (SPSS), version 23 (IBM Corp., NY, USA). Fisher's exact method was used for the categorical variables and analysis of variance (ANOVA) was used for the continuous variables.

Results
=======

The total number of patients included in the study were 50 (n=50). The indication for prescription of WCD was ischemic cardiomyopathy in 46% (23/50) of patients and non-ischemic cardiomyopathy in 54% (27/50) of patients. The descriptive statistics showed that the mean age of the population was 60.7 years, 66% (33/50) of patients were male, 64% (32/50) were Caucasian, 40% (20/50) had diabetes, 76% (38/50) had hypertension, 34% (28/50) had chronic kidney disease, 56% (28/50) had coronary artery disease, 32% (16/50) had New York Heart Association category III or IV. The median follow-up time was three months (103.5 days) and the mean follow-up was 150 days (Table [1](#TAB1){ref-type="table"}).

###### Baseline characteristics and demographics of the sample

  ---------------------------------------------------------- ---------- ----------- ----
  Variable                                                   n          Percent %   
  Gender                                                     Female     17          34
  Male                                                       33         66          
  Indications for Wearable Cardioverter Defibrillator        Ischemic   23          46
  Non-Ischemic                                               27         54          
  Implanted Cardioverter Defibrillator (ICD) placed or Not   No ICD     39          78
  ICD placed                                                 11         22          
  History of Hypertension                                    No         12          24
  Yes                                                        38         76          
  History of Diabetes Mellitus                               No         30          60
  Yes                                                        20         40          
  History of Chronic Kidney Disease                          Absent     33          66
  Present                                                    17         34          
  Patients on Anti-arrhythmic Medication                     No         33          66
  Yes                                                        17         34          
  ---------------------------------------------------------- ---------- ----------- ----

The patients were divided into two groups i.e., with ICD placement or without ICD placement, based on whether implantable cardioverter defibrillator was inserted or not. ICD was placed in 22% (11/50) patient and no ICD was placed in 78% (39/50) patients. Mean left ventricular ejection fraction (LVEF) in the group with ICD placement was 32.7% (95% confidence interval (CI); 27.6% - 37.9%) which decreased by 4.5% to reach a mean LVEF of 28.6% (95% CI; 12.2% - 44.9%) compared to the group without ICD placement which had a mean LVEF of 25.9% (95% CI; 23.8% - 27.9%) and it increased by 17.3% to reach a mean LVEF of 44.6% (95% CI; 41.1% - 48.2%) with a statistical significance in ANOVA (Table [2](#TAB2){ref-type="table"}). Patients in the ICD group were followed for a mean of 78 days (range; 61 - 96) compared to No ICD placed group which were followed for a mean of 162 days (range; 104 - 220).

###### Comparison outcomes between the two groups based on eventual implantation of a permanent device

ICD: implantable cardiac defibrillator.

  -------------------------------------- ------------- ---------------------------------- --------- -------- -----------
                                         Mean          95% Confidence Interval for Mean   P Value            
  Lower Bound                            Upper Bound                                                         
  Age                                    No ICD        59.949                             55.963    63.935     0.382
  ICD placed                             63.545        56.465                             70.626             
  Total                                  60.740        57.351                             64.129             
  Ejection Fraction on Fit Date          No ICD        25.868                             23.798    27.939     0.005
  ICD placed                             32.778        27.639                             37.917             
  Total                                  27.191        25.173                             29.210             
  Ejection Fraction at last follow up    No ICD        44.629                             41.083    48.174     0.003
  ICD placed                             28.600        12.207                             44.993             
  Total                                  42.625        38.847                             46.403             
  Difference between Ejection fraction   No ICD        17.259                             13.172    21.346     \<0.000
  ICD placed                             -4.500        -13.148                            4.148              
  Total                                  13.303        8.680                              17.926             
  Days between follow up                 No ICD        162.20                             104.01    220.39    
  ICD placed                             78.67         61.20                              96.13              
  Total                                  149.98        99.75                              200.20             
  -------------------------------------- ------------- ---------------------------------- --------- -------- -----------

Discussion
==========

The current recommendations for WCD come from the American Heart Association, American College of Cardiology and Heart Rhythm Society guidelines for the management of patients with ventricular arrhythmias and prevention of SCD \[[@REF6]\]. Currently WCD is placed within 40 days of a new myocardial infarction with low LVEF, reduced EF (less than 35%) in a patient within 90 days post coronary artery bypass grafting (CABG), potentially reversible nonischemic cardiomyopathy with severely reduced LVEF less than 35%, and severe heart failure patients waiting for heart transplant \[[@REF6]\].

Our study investigated 50 patients with both ischemic and non-ischemic cardiomyopathy with EF lower than 35%. The patients were on guideline-directed medical therapy (GDMT) while wearing WCD and only 22% patients ended up needing an ICD implantation per ACC/AHA guidelines while 78% had significant improvement in EF and did not require placement of an ICD. None of the patients received a shock from the WCD and all patients survived. The ICD placement group had reduction in EF which was due to the progression of the underlying disease process despite being on GDMT. The number needed to treat could not be calculated as no treatments were dispensed and this was perhaps due to the limitation imposed by the small sample size. The patients in the no ICD placement period were followed for a longer duration until there was a documented increase in EF which did not warrant the placement of ICD.

Vest Prevention of Early Sudden Death Trial (VEST trial) reported that the rate of arrhythmic deaths did not differ in patients wearing a WCD while on GDMT compared to those who were only taking GDMT and not wearing WCD. This trial targeted the same demographic as our analysis, and investigated patients soon after an acute myocardial infarction with reduced EF of 35% or lower \[[@REF7]\]. However, the trial was considered underpowered to determine the beneficial effect of WCD. A recent meta-analysis by Masri et al. \[[@REF8]\], that included 27 observational studies and one randomized controlled trial (RCT) which was the VEST trial mentioned above, demonstrated that mortality in patients wearing WCD was rare at 0.7 per 100 patients in first three months. The study concluded that appropriately treated patients with WCD were higher in observational studies than the VEST trial owing to the significant heterogeneity in the methodology of the included studies.

VEST trial demonstrated the inconvenience of using WCD as a major limitation for the device. This was manifested as a lower than expected adherence to WCD use in a closely followed sample \[[@REF7]\]. In our study, all patients reported compliance with WCD but follow up was admittedly less focused on investigating device adherence than in VEST trial.

Moreover, inappropriate shocks are a major concern for ICDs as they occur in about 40% of patients with ICD \[[@REF9]-[@REF10]\] and there is an increased risk of death in patients who received shock appropriately (for VT) or inappropriately \[[@REF11]-[@REF12]\]. In the cohort we studied, there were no inappropriate shocks reported during the course of follow up and this endorses the safety of this device. A study detailing three-year experience with WCDs, published from France, did not show any appropriate shocks and one inappropriate shock which is similar to the results we saw in a much smaller sample \[[@REF13]\]. There was another study published out of Germany that analyzed six years of data and reported one appropriate and two inappropriate shocks \[[@REF14]\].

The current review of the literature and our findings suggest that more studies are needed to effectively report the efficacy and safety of WCD for primary prevention of life-threatening arrhythmias.

Conclusions
===========

Almost a quarter of the patients that were prescribed WCD in our center ended up with an implanted device which demonstrates appropriate use. Equally important was the observed safety of WCDs as a treatment modality with no inappropriate shocks recorded in the followed cohort.
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